Well HealthCare Technologies Completes Nearly RMB 100 Million Series A+ Financing to Advance Its '3T' Multi-Omics Precision Diagnostics Platform

VCBeat (WeChat: vcbeat) has learned that in June 2021, Hangzhou Huijian Technology Co., Ltd. (hereinafter referred to as “Huijian Technology”) completed a Series A+ financing round of nearly RMB 100 million. The round was co-led by Longmen Capital and Tianhui Capital, with participation from TusPark Ventures and the Jiyang Talent Fund. Existing shareholder Leiyu Capital continued to increase its investment. WinX Capital served as the exclusive financial advisor.

Upon completion of this round of financing, the Company will further consolidate its “3T”-based multi-omics precision diagnostics platform, prioritize the advancement of real-world clinical studies and the development of multi-omics precision diagnostic products, expand into additional clinical application scenarios with unmet needs, build a high-throughput clinical mass spectrometry application ecosystem, and accelerate the industrialization and commercialization of its core products and services.

Huijian Technology’s “3T” multi-omics precision diagnostics platform comprises an innovative diagnostic methodology system integrating MT (Materials Technology), BT (Biotechnology), and IT (Information Technology). The company has successfully developed high-throughput clinical mass spectrometry and artificial olfaction system platforms at the international forefront, and has established a product development and application framework suitable for diverse sample types, multi-omics testing, and varied clinical scenarios.

The company boasts a diverse product portfolio. In the field of high-throughput clinical mass spectrometry, it offers systematic products and service solutions, including nano-mass spectrometry chips and consumables suitable for multi-omics detection such as genomics, peptidomics, and metabolomics; Bio-pSiTM mass spectrometry analysis kits; Clin-MS Plat® high-throughput mass spectrometers; and Huijian Zhiyun® AI diagnostic software. In the realm of artificial olfaction systems, the company’s offerings cover BreTraceTM nano-gas sensor components, XBreathTM health testing devices based on exhaled breath metabolomics, and iAOS® precision diagnostic software, thereby addressing significant potential needs in non-invasive clinical diagnosis and home-based chronic disease management.

To date, the company has secured dozens of domestic and international intellectual property rights. Several products, recognized as the first of their kind in China, have entered pilot production and large-scale clinical development stages. The LungScrTM pulmonary health screening project, focused on salivary metabolomics, and the CanFinder® multi-cancer screening project have accumulated clinical sample data from thousands of cases across multiple centers.

Huijian Technology’s Multi-Omics Precision Diagnostic Platform Based on “3T”

Ren Liang, General Manager of Hangzhou Huijian Technology Co., Ltd., stated that the robust growth of innovative technology companies is inseparable from capital support. Since its establishment, the company has completed three rounds of institutional fundraising and has received investment and recognition from multiple renowned funds, including the investors in this round. This financing will advance the company’s engineering, product development, and regulatory registration efforts in the field of first-in-class innovative diagnostics.

Professor Wu Jianmin, Founder of Huijian Technology, stated: “We extend our sincere gratitude to both new and existing shareholders, as well as Kaisheng Capital, our partner in this round of financing, for their strong support. Huijian Technology is dedicated to making precision medicine accessible and affordable, playing a vital role in tumor screening, auxiliary diagnosis, medication guidance, treatment efficacy monitoring, and chronic disease management, thereby contributing to the advancement of human health.”

Mr. Wang Haining, Founding Partner of Longmen Capital, stated:

Precision diagnosis and early screening of tumors have emerged as one of the hottest trends in the pharmaceutical industry in recent years, characterized by substantial clinical demand and significant technical challenges. Leveraging the MALDI-TOF mass spectrometry platform, Hangzhou Huijian Technology Co., Ltd. has established a novel methodological framework through characteristic analysis of tumor peptide profiles. By integrating its proprietary nano-chips with deep learning algorithms, the company has substantially enhanced the accuracy of peptide profiles as tumor biomarkers. This innovation promotes the widespread adoption of MALDI-TOF technology in the field of precision tumor diagnosis and screening, delivering considerable clinical and commercial value.

Mr. Yuan Angen, Chairman of Tianhui Capital, stated：

Hangzhou Huijian Technology Co., Ltd. boasts a core team with extensive experience and innovative capabilities in materials science, mass spectrometry applications, medicine, bioinformatics, and the industrialization of in vitro diagnostics (IVD). The company has developed nanochips with independent intellectual property rights, which address critical bottlenecks in the capture and enrichment processes for the industrial application of peptidomics. Furthermore, it has established a translational platform for scientific research and clinical applications in proteomics and peptidomics based on mass spectrometry analysis. After decades of development, genomics has accumulated vast amounts of genomic data, and its conditions for industrialization have become relatively mature, creating new opportunities for the advancement of functional genomics, proteomics, and peptidomics. In light of this, we have chosen to partner with Hangzhou Huijian Technology Co., Ltd. to support the development and application of its proteomics and peptidomics technologies in pharmaceutical R&D, clinical diagnosis, and life health sectors. We look forward to the early completion of clinical validation for Huijian Technology’s products and applications, enabling them to better serve the cause of human health.

Ms. Liu Huiqin, Partner at TusPark Ventures, stated:

As a fund focused on investing in innovative medical devices in China, TusPark Ventures has consistently paid close attention to domestic enterprises with core technologies in fields such as molecular diagnostics and multi-omics precision diagnostics. Hangzhou Huijian Technology Co., Ltd. is a rare find; under the leadership of Professor Wu, the team has established solid, proprietary technological expertise in nanomaterials and chip technology, as well as nano-gas sensor technology. Leveraging this foundational technology and through a high-throughput clinical mass spectrometry platform, they have accumulated research sample testing data from over ten thousand cases in disease-related peptidomics detection. Huijian Technology is currently advancing its peptidomics-based colorectal cancer detection kit toward clinical application, which is poised to become the world’s first peptidomics-based screening product for colon cancer. This innovation holds great promise for significantly addressing the current challenges of high costs, poor patient experience, and low compliance associated with colorectal cancer testing. Additionally, Huijian Technology is developing inflammatory breath-sensing diagnostic products, with the potential to expand into breath-based detection for multiple conditions, including tumors. We observe that international capital markets have highly valued and affirmed both of these technologies with significant premiums. We believe that Huijian Technology will emerge as a prominent representative of Chinese enterprises in this high-tech field.

Mr. Zheng Mingming of the Jiyang Talent Fund stated:

Early cancer screening is still in its nascent stages, with substantial room for future growth and no perfect solution currently available. As a cutting-edge technology transitioning from research to clinical application, mass spectrometry has long been a key focus of Rushan Capital. Hangzhou Huijian Technology Co., Ltd. has applied its proprietary nanomaterials to MALDI-TOF mass spectrometry, achieving prominent advantages including high specificity, high sensitivity, high-throughput detection, and low cost. The company has accumulated extensive clinical data across various cancers, such as colorectal, gastric, liver, and breast cancers, demonstrating significant investment value. We are honored to participate in this round of financing for Hangzhou Huijian Technology.

Mr. Cai Wei, Chairman of Leiyu Capital, stated:

As a medical-focused angel investor, Leiyu Capital is dedicated to identifying innovative healthcare companies with platform potential. Clinical mass spectrometry testing is poised to become the next major growth frontier in the IVD sector. Hangzhou Huijian Technology Co., Ltd. has developed a comprehensive untargeted mass spectrometry detection system—integrating instruments, reagents, software, and algorithmic models—by leveraging its laser desorption/ionization mass spectrometry platform and converging technologies such as nanomaterials, mass spectrometry, and artificial intelligence. This high-barrier mass spectrometry platform provides innovative, integrated solutions for early cancer screening and precision diagnosis. We have increased our investment in this A+ round, reaffirming our strong confidence in Huijian’s team and technology!

Mr. Zou Guowen, Founding Partner of Kaicheng Capital, stated:

Kaicheng Capital is honored to have assisted Huijian Technology in securing this round of financing. Huijian Technology boasts an exceptionally strong founding team and stands as a rare high-quality company in China’s IVD sector with core technological innovation capabilities. Its technology platform offers both scalability and high-growth product potential. The company’s innovative methodological system has achieved revolutionary advancements in accuracy, ease of use, and cost control. We believe that, with the support of more prominent shareholders, Huijian Technology will emerge as a dark horse leading the era of multi-omics precision diagnostics.

Mr. Zhao Weiwen, Managing Partner of Miracle Light at BGI, stated:

Huijian is among the first batch of companies in China to employ multi-omics approaches for early cancer screening. Miracle Light has been honored to serve as Huijian’s first institutional investor, accompanying the company on its journey and growing together along the way. Our most profound impression is that Huijian’s team, from top to bottom, has consistently maintained a down-to-earth, diligent, low-key, and pragmatic work style, advancing steadily with each step. Today, the early cancer screening landscape has changed dramatically. With its robust products, Huijian has garnered significant attention and recognition. We hope Huijian will adopt a higher profile, enabling more like-minded partners to learn about its goals and vision and join in its mission. Ahead lies a vast expanse of possibilities.

Ms. Wan Jin, Executive General Manager of SDIC Venture Capital, stated:

The clinical mass spectrometry testing industry is a key focus area in the national plan for scientific and technological innovation. Hangzhou Huijian Technology Co., Ltd. boasts internationally leading MALDI target materials and a tumor peptide profiling biomarker discovery platform. Its products deliver superior performance, addressing the industry-wide challenges of enriching low-abundance proteins and preventing their degradation. The products have already demonstrated excellent clinical data in early screening for colorectal cancer. SDIC Venture Capital has continuously invested in Huijian Technology across multiple rounds, starting from the angel round. SDIC recognizes the long-term expertise and significant growth potential of Professor Wu Jianmin’s team in the clinical mass spectrometry testing sector, and supports Huijian’s R&D investments and business line expansion.

Mr. Wu Yuding, Investment Director at Huarui Capital, stated:

Early screening and auxiliary diagnosis of diseases, including tumors, hold significant social significance and value; the era of shifting disease diagnosis and treatment upstream is imminent. Hangzhou Huijian Technology Co., Ltd. has creatively applied nanotechnology to fields such as mass spectrometry-based metabolomics and peptidomics analysis, liquid and tissue biopsy, gas sensing and artificial olfaction, and salivary metabolomics analysis. Its key performance indicators, including sensitivity and resolution, are globally leading, and the company has achieved numerous substantive results. We look forward to Hangzhou Huijian Technology making unique contributions to human health under the leadership of Professor Wu.

Mr. Liu Xiaolong, Investment Director at Yanmucao Capital, stated:

Having journeyed with Huijian from the beginning, we have grown from an initial team of six to a multi-departmental collaborative force. Every timeline and every plan has been successfully executed, regardless of the pressure or difficulties encountered. Meticulous craftsmanship and diligent effort inevitably lead to success. We wish Hangzhou Huijian Technology Co., Ltd. smooth sailing in its future endeavors and look forward to a healthier, better world brought about by its innovations.

About Longmen Capital:

Longmen Capital is a specialized venture capital firm in the pharmaceutical industry, focusing on research and early-stage investment in innovative pharmaceuticals and biotechnology. All team members have backgrounds in medicine or biology and possess many years of industry experience. Since its establishment in 2017, Longmen Capital has invested in more than 30 innovative pharmaceutical companies, with assets under management exceeding RMB 2 billion.

About TusPark Capital:

Tianhui Capital (comprising Tianhui Hongyou and Tianhui Sumitomo Mitsui Banking Corporation) is a value investor and navigator deeply rooted in the healthcare industry. The company’s core team has 20 years of experience in investment management within the medical and health sectors. It adopts a “Four-Pronged” investment strategy characterized by specialization, early-stage focus, platform-based operations, and internationalization, with a focus on key areas such as precision medicine, high-end medical devices, innovative drugs, and novel therapeutic technologies. Tianhui Capital has systematically established a unique post-investment management system based on the “1+1+N” framework, including the “3+3” model and the “100-Day Navigation Support” program. Through professional post-investment value-added services, it accelerates the innovative transformation and leapfrog development of China’s healthcare industry and its portfolio companies.

About TusPark Ventures:

TusPark Ventures is a key venture capital management platform within Tsinghua University’s innovation ecosystem. Committed to investing in technology-driven enterprises, it focuses on high-tech, high-growth companies with core competitiveness during their early and growth stages, with a particular emphasis on the life sciences sector. It has invested in a portfolio of outstanding medical device companies.

About the Jiyang Talent Fund:

The Jiyang High-Level Talent Fund is a specialized regional fund managed by Rushan Capital, primarily investing in high-level talent-led startups that align with the industrial development plan of Zhuji City. Rushan Capital (CRESTVALUE) is a venture capital firm specializing in equity investments in high-tech, high-growth enterprises, with a focus on emerging sectors such as broad security, artificial intelligence, healthcare, and new energy vehicles. The company has been successively appointed as Vice President Unit of the Equity and Venture Capital Professional Committee of the Investment Association of China, Vice President Unit of the Zhongguancun Equity Investment Association, and Vice President Unit of the Zhejiang Venture Capital Association. It was honored among the “Top 100 Best Venture Capital Institutions in China 2019” by Financing China and named “China’s Annual Venture Capital Institution 2019,” and has been consecutively ranked among the “Top 10 Venture Capital Institutions in Zhejiang” for ten years.

About Leiyu Capital:

Lei Yu Capital is an emerging early-stage investment firm focused on the healthcare sector. It pioneered the “TOP A” investment philosophy, which prioritizes investing in individuals, specifically targeting life scientists and physician entrepreneurs. With deep expertise in the medical industry, the firm leverages its professional capabilities, extensive resources, networks, and channels to provide portfolio companies with specialized support in subsequent financing rounds, strategic planning, partnership development, resource matchmaking, senior talent acquisition, establishment of advanced corporate governance systems, and mergers and acquisitions.

About WinX Capital:

WinX Capital is a leading investment bank in China’s healthcare sector. Five members of its founding team hold Ph.D. degrees in Global Finance from the PBC School of Finance, Tsinghua University. Its frontline team boasts an average of over 10 years of experience in management, investment, and mergers and acquisitions (M&A), with cumulative transaction values exceeding RMB 30 billion. Headquartered in Beijing and Shanghai, WinX Capital serves more than 3,000 active institutional investors and industrial groups. In 2020, it was ranked among the “Top 5 Most Promising New-Type Investment Banks in China” by 36Kr’s WISE 2020 list, and named one of the “Top 4 Best Financial Advisory Firms in Healthcare” for 2020 by Qiming Technology & Xinsheng Chuangfu.